Literature DB >> 24215172

The prevalence and contents of advance directives in patients with pacemakers.

Dario Pasalic1, Tanya H Tajouri, Abigale L Ottenberg, Paul S Mueller.   

Abstract

BACKGROUND: Little is known about the use of advance directives (ADs) in patients who have implantable cardiac pacemakers (PMs).
METHODS: We conducted a retrospective review of the medical records of residents of Olmsted County, Minnesota, who underwent implantation of a cardiac PM at Mayo Clinic (Rochester, Minnesota) during 2006 and 2007, and determined the prevalence and contents of ADs in these patients.
RESULTS: During the study period, 205 residents of Olmsted County (men, 53%) underwent PM implantation (mean age [standard deviation] at implantation, 77 [15] years). Overall, 120 patients (59%) had ADs. Of these, 63 ADs (53%) were executed more than 12 months before and 33 (28%) were executed after PM implantation. Many patients specifically mentioned life-prolonging treatments in their ADs: cardiopulmonary resuscitation, 76 (63%); mechanical ventilation, 56 (47%); and hemodialysis, 31 (26%). Pain control was mentioned in 79 ADs (66%) and comfort measures were mentioned in 42 ADs (35%). Furthermore, the AD of many patients contained a general statement about end-of-life care (e.g., no "heroic measures"). However, only one AD (1%) specifically addressed the end-of-life management of the PM.
CONCLUSIONS: More than half of the patients with PMs in our study had executed an AD, but only one patient specifically mentioned her PM in her AD. These results suggest that patients with PMs should be encouraged to execute ADs and specifically address end-of-life device management in their ADs. Doing so may prevent end-of-life ethical dilemmas related to PM management. ©2013 Mayo Foundation for Medical Education and Research Pacing and Clinical Electrophysiology ©2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  advance directives; end-of-life care; ethics; pacemakers

Mesh:

Year:  2013        PMID: 24215172      PMCID: PMC3981886          DOI: 10.1111/pace.12287

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  15 in total

1.  HRS Expert Consensus Statement on the Management of Cardiovascular Implantable Electronic Devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy.

Authors:  Rachel Lampert; David L Hayes; George J Annas; Margaret A Farley; Nathan E Goldstein; Robert M Hamilton; G Neal Kay; Daniel B Kramer; Paul S Mueller; Luigi Padeletti; Leo Pozuelo; Mark H Schoenfeld; Panos E Vardas; Debra L Wiegand; Richard Zellner
Journal:  Heart Rhythm       Date:  2010-05-14       Impact factor: 6.343

2.  Advance health planning and treatment preferences among recipients of implantable cardioverter defibrillators: an exploratory study.

Authors:  Jeffrey T Berger; Matthew Gorski; Todd Cohen
Journal:  J Clin Ethics       Date:  2006

3.  EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy.

Authors:  Luigi Padeletti; David O Arnar; Lorenzo Boncinelli; Johannes Brachman; John A Camm; Jean Claude Daubert; Sarah K Hassam; Sarah Kassam; Luc Deliens; Michael Glikson; David Hayes; Carsten Israel; Rachel Lampert; Trudie Lobban; Pekka Raatikainen; Gil Siegal; Panos Vardas; Paulus Kirchhof; Rüdiger Becker; Francisco Cosio; Peter Loh; Stuart Cobbe; Andrew Grace; John Morgan
Journal:  Europace       Date:  2010-07-30       Impact factor: 5.214

4.  The use of advance directives among patients with left ventricular assist devices.

Authors:  Keith M Swetz; Paul S Mueller; Abigale L Ottenberg; Chadi Dib; Monica R Freeman; Daniel P Sulmasy
Journal:  Hosp Pract (1995)       Date:  2011-02

5.  Implantation trends and patient profiles for pacemakers and implantable cardioverter defibrillators in the United States: 1993-2006.

Authors:  Steven M Kurtz; Jorge A Ochoa; Edmund Lau; Yakov Shkolnikov; Behzad B Pavri; Daniel Frisch; Arnold J Greenspon
Journal:  Pacing Clin Electrophysiol       Date:  2010-01-04       Impact factor: 1.976

Review 6.  Contemporary pacemakers: what the primary care physician needs to know.

Authors:  Karoly Kaszala; Jose F Huizar; Kenneth A Ellenbogen
Journal:  Mayo Clin Proc       Date:  2008-10       Impact factor: 7.616

7.  Ethical analysis of withdrawal of pacemaker or implantable cardioverter-defibrillator support at the end of life.

Authors:  Paul S Mueller; C Christopher Hook; David L Hayes
Journal:  Mayo Clin Proc       Date:  2003-08       Impact factor: 7.616

8.  Deactivating implanted cardiac devices in terminally ill patients: practices and attitudes.

Authors:  Paul S Mueller; Sarah M Jenkins; Katrina A Bramstedt; David L Hayes
Journal:  Pacing Clin Electrophysiol       Date:  2008-05       Impact factor: 1.976

9.  Features and outcomes of patients who underwent cardiac device deactivation.

Authors:  Lillian C Buchhalter; Abigale L Ottenberg; Tracy L Webster; Keith M Swetz; David L Hayes; Paul S Mueller
Journal:  JAMA Intern Med       Date:  2014-01       Impact factor: 21.873

10.  Patients who complete advance directives and what they prefer.

Authors:  Adam Nishimura; Paul S Mueller; Laura K Evenson; Lisa L Downer; Catherine T Bowron; Michael P Thieke; Diane M Wrobleski; Mary E Crowley
Journal:  Mayo Clin Proc       Date:  2007-12       Impact factor: 7.616

View more
  2 in total

1.  Prevalence and Contents of Advance Directives of Patients with ESRD Receiving Dialysis.

Authors:  Molly A Feely; Daniel Hildebrandt; Jithinraj Edakkanambeth Varayil; Paul S Mueller
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-17       Impact factor: 8.237

2.  Content analysis of Advance Directives completed by patients with advanced cancer as part of an Advance Care Planning intervention: insights gained from the ACTION trial.

Authors:  Marieke Zwakman; J J M van Delden; G Caswell; L Deliens; F Ingravallo; L J Jabbarian; A T Johnsen; I J Korfage; A Mimić; C Møller Arnfeldt; N J Preston; M C Kars
Journal:  Support Care Cancer       Date:  2019-07-05       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.